Stock Analysis

The Conformis (NASDAQ:CFMS) Share Price Is Up 139% And Shareholders Are Boasting About It

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you pick the right stock, you can make a lot more than 100%. For example, the Conformis, Inc. (NASDAQ:CFMS) share price has soared 139% return in just a single year. Better yet, the share price has gained 263% in the last quarter. The company reported its financial results recently; you can catch up on the latest numbers by reading our company report. In contrast, the longer term returns are negative, since the share price is 47% lower than it was three years ago.

See our latest analysis for Conformis

Given that Conformis didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

Conformis grew its revenue by 17% last year. We respect that sort of growth, no doubt. While that revenue growth is pretty good the share price performance outshone it, with a lift of 139% as mentioned above. If the profitability is on the horizon then now could be a very exciting time to be a shareholder. Of course, we are always cautious about succumbing to 'fear of missing out' when a stock has shot up strongly.

You can see how revenue and earnings have changed over time in the image below, (click on the chart to see cashflow).

NasdaqGS:CFMS Income Statement, May 14th 2019
NasdaqGS:CFMS Income Statement, May 14th 2019

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

A Different Perspective

It's nice to see that Conformis shareholders have gained 139% (in total) over the last year. What is absolutely clear is that is far preferable to the dismal 19% average annual loss suffered over the last three years. We're generally cautious about putting too much weigh on shorter term data, but the recent improvement is definitely a positive. If you would like to research Conformis in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

About NasdaqCM:CFMS

Conformis

Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation.

Fair value with mediocre balance sheet.

Weekly Picks

AL
RKLB logo
AlexLovell on Rocket Lab ·

Early mover in a fast growing industry. Likely to experience share price volatility as they scale

Fair Value:US$16.25377.2% overvalued
43 users have followed this narrative
0 users have commented on this narrative
14 users have liked this narrative
AG
Agricola
EXN logo
Agricola on Excellon Resources ·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.3% undervalued
50 users have followed this narrative
7 users have commented on this narrative
15 users have liked this narrative
FU
FundamentallySarcastic
CCP logo
FundamentallySarcastic on Credit Corp Group ·

Moderation and Stabilisation: HOLD: Fair Price based on a 4-year Cycle is $12.08

Fair Value:AU$12.6411.9% overvalued
8 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative

Updated Narratives

IN
Investingwilly
NFLX logo
Investingwilly on Netflix ·

Positioned to Win as the Streaming Wars Settle

Fair Value:US$135.0231.0% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
YI
META logo
yiannisz on Meta Platforms ·

Meta’s Bold Bet on AI Pays Off

Fair Value:US$723.118.5% undervalued
33 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
YI
ADP logo
yiannisz on Automatic Data Processing ·

ADP Stock: Solid Fundamentals, But AI Investments Test Its Margin Resilience

Fair Value:US$387.7733.0% undervalued
14 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

RO
RockeTeller
SCZ logo
RockeTeller on Santacruz Silver Mining ·

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

Fair Value:CA$8685.5% undervalued
83 users have followed this narrative
8 users have commented on this narrative
23 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$250.3926.6% undervalued
981 users have followed this narrative
6 users have commented on this narrative
26 users have liked this narrative
RO
RobertoAllende
NVDA logo
RobertoAllende on NVIDIA ·

The AI Infrastructure Giant Grows Into Its Valuation

Fair Value:US$345.0746.8% undervalued
44 users have followed this narrative
28 users have commented on this narrative
24 users have liked this narrative